OÄ Dr. Ursula Vogl, Barmherzige Schwestern Krankenhaus Wien, berichtet von Nierenzellkarzinom (RCC)-Ergebnissen, wonach Patienten mit sarkomatoider Histologie besonders von einer Immuntherapie profitieren. Neue Daten sprechen auch für deren Einsatz bei Patienten mit Hirnmetastasen oder Autoimmunerkrankung.

*Korrektur zum Video: korrekt ist Atezolizumab und Bevacizumab

Abstracts, die im Video diskutiert werden:

Abstract 4500
Pembrolizumab (pembro) plus axitinib (axi) versus sunitinib as first-line therapy for metastatic renal cell carcinoma (mRCC): Outcomes in the combined IMDC intermediate/poor risk and sarcomatoid subgroups of the phase 3 KEYNOTE-426 study.
Brian I. Rini

Poster Board: #338 • Abstract 4512
Atezolizumab (atezo) + bevacizumab (bev) versus sunitinib (sun) in pts with untreated metastatic renal cell carcinoma (mRCC) and sarcomatoid (sarc) histology: IMmotion151 subgroup analysis.
Brian I. Rini

Poster Board: #339, Abstract 4513
CheckMate 214 post-hoc analyses of nivolumab plus ipilimumab or sunitinib in IMDC intermediate/poor-risk patients with previously untreated advanced renal cell carcinoma with sarcomatoid features.
David F. McDermott

Poster Board: #397, Abstract 4571
Retrospective analysis of the safety and efficacy of immune checkpoint inhibitors (CPI) among patients (pts) with pre-existing autoimmune disorders (AD) and renal cell carcinoma (RCC) or urothelial carcinoma (UC).
Nieves Martinez Chanza,

Poster Board: #343, Abstract 4517
Safety and efficacy of nivolumab plus ipilimumab (NIVO+IPI) in patients with advanced renal cell carcinoma (aRCC) with brain metastases: Interim analysis of CheckMate 920.
Hamid Emamekhoo

Abstract 4508
Cytoreductive nephrectomy (CN) in metastatic renal cancer (mRCC): Update on Carmena trial with focus on intermediate IMDC-risk population.
Arnaud Mejean

Uro-Onkologie